159 related articles for article (PubMed ID: 23600946)
1. Drug-induced hypo- and hyperprolactinemia: mechanisms, clinical and therapeutic consequences.
Voicu V; Medvedovici A; Ranetti AE; Rădulescu FŞ
Expert Opin Drug Metab Toxicol; 2013 Aug; 9(8):955-68. PubMed ID: 23600946
[TBL] [Abstract][Full Text] [Related]
2. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole.
Lu ML; Shen WW; Chen CH
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1978-81. PubMed ID: 18848860
[TBL] [Abstract][Full Text] [Related]
3. [Antipsychotic-drug-induced hyperprolactinemia: physiopathology, clinical features and guidance].
Besnard I; Auclair V; Callery G; Gabriel-Bordenave C; Roberge C
Encephale; 2014 Feb; 40(1):86-94. PubMed ID: 23928066
[TBL] [Abstract][Full Text] [Related]
4. Positron emission tomography measurement of dopamine D₂ receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia.
Arakawa R; Okumura M; Ito H; Takano A; Takahashi H; Takano H; Maeda J; Okubo Y; Suhara T
J Clin Psychiatry; 2010 Sep; 71(9):1131-7. PubMed ID: 20361897
[TBL] [Abstract][Full Text] [Related]
5. Differential add-on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics.
Chen CK; Huang YS; Ree SC; Hsiao CC
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Dec; 34(8):1495-9. PubMed ID: 20732372
[TBL] [Abstract][Full Text] [Related]
6. Hyperprolactinemia with aripiprazole: understanding the paradox.
Saraf G; Behere RV; Venkatasubramanian G; Rao NP; Varambally S; Gangadhar BN
Am J Ther; 2014; 21(3):e80-1. PubMed ID: 22357167
[TBL] [Abstract][Full Text] [Related]
7. Prolactinemia is uncoupled from central D2/D3 dopamine receptor occupancy in amisulpride treated patients.
Bressan RA; Erlandsson K; Spencer EP; Ell PJ; Pilowsky LS
Psychopharmacology (Berl); 2004 Sep; 175(3):367-73. PubMed ID: 14997280
[TBL] [Abstract][Full Text] [Related]
8. The disparity of pharmacokinetics and prolactin study for risperidone long-acting injection.
Peng PW; Huang MC; Tsai CJ; Pan CH; Chen CC; Chiu CC
J Clin Psychopharmacol; 2008 Dec; 28(6):726-7; author reply 727-8. PubMed ID: 19011459
[No Abstract] [Full Text] [Related]
9. Aripiprazole reverses paliperidone-induced hyperprolactinemia.
Basterreche N; Zumárraga M; Arrue A; Olivas O; Dávila W
Actas Esp Psiquiatr; 2012; 40(5):290-2. PubMed ID: 23076612
[TBL] [Abstract][Full Text] [Related]
10. Hyperprolactinaemia on depot risperidone treated with aripiprazole.
Anandarajan T; Tibrewal P; Dhillon R; Bastiampillai T
Aust N Z J Psychiatry; 2012 Aug; 46(8):792-3. PubMed ID: 22528973
[No Abstract] [Full Text] [Related]
11. Aripiprazole resolves amisulpride and ziprasidone-induced hyperprolactinemia.
Saitis M; Papazisis G; Katsigiannopoulos K; Kouvelas D
Psychiatry Clin Neurosci; 2008 Oct; 62(5):624. PubMed ID: 18950388
[No Abstract] [Full Text] [Related]
12. Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels.
Knegtering R; Baselmans P; Castelein S; Bosker F; Bruggeman R; van den Bosch RJ
Am J Psychiatry; 2005 May; 162(5):1010-2. PubMed ID: 15863810
[TBL] [Abstract][Full Text] [Related]
13. Prediction and assessment of extrapyramidal side effects induced by risperidone based on dopamine D(2) receptor occupancy.
Yamada Y; Ohno Y; Nakashima Y; Fukuda M; Takayanagi R; Sato H; Tsuchiya F; Sawada Y; Iga T
Synapse; 2002 Oct; 46(1):32-7. PubMed ID: 12211096
[TBL] [Abstract][Full Text] [Related]
14. Using aripiprazole to attenuate paliperidone-induced hyperprolactinemia.
Rocha FL; Hara C; Ramos MG
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Aug; 34(6):1153-4. PubMed ID: 20547197
[No Abstract] [Full Text] [Related]
15. A cross-sectional study of plasma risperidone levels with risperidone long-acting injectable: implications for dopamine D2 receptor occupancy during maintenance treatment in schizophrenia.
Ikai S; Remington G; Suzuki T; Takeuchi H; Tsuboi T; Den R; Hirano J; Tsunoda K; Nishimoto M; Watanabe K; Mimura M; Mamo D; Uchida H
J Clin Psychiatry; 2012 Aug; 73(8):1147-52. PubMed ID: 22967779
[TBL] [Abstract][Full Text] [Related]
16. The effect of the Taq1A variant in the dopamine D₂ receptor gene and common CYP2D6 alleles on prolactin levels in risperidone-treated boys.
Roke Y; van Harten PN; Franke B; Galesloot TE; Boot AM; Buitelaar JK
Pharmacogenet Genomics; 2013 Sep; 23(9):487-93. PubMed ID: 23851570
[TBL] [Abstract][Full Text] [Related]
17. Impact of different antidopaminergic mechanisms on the dopaminergic control of prolactin secretion.
Veselinović T; Schorn H; Vernaleken IB; Schiffl K; Klomp M; Gründer G
J Clin Psychopharmacol; 2011 Apr; 31(2):214-20. PubMed ID: 21346608
[TBL] [Abstract][Full Text] [Related]
18. Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite.
Melkersson KI
Hum Psychopharmacol; 2006 Dec; 21(8):529-32. PubMed ID: 17094165
[TBL] [Abstract][Full Text] [Related]
19. Antipsychotic-induced hyperprolactinemia.
Bostwick JR; Guthrie SK; Ellingrod VL
Pharmacotherapy; 2009 Jan; 29(1):64-73. PubMed ID: 19113797
[TBL] [Abstract][Full Text] [Related]
20. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review.
Peuskens J; Pani L; Detraux J; De Hert M
CNS Drugs; 2014 May; 28(5):421-53. PubMed ID: 24677189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
